Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of sacubitril/valsartan on serum potassium in anuric hemodialysis patients
ChiCTR2300074610Phase 4Not yet recruiting
- Sponsor
- Peking University Shougang Hospital
- Start
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of sacubitril + valsartan in end-stage kidney disease (ESKD) and heart failure (HF), sponsored by Peking University Shougang Hospital. Primary endpoints: Mean serum potassium and Peak serum potassium. Planned start Aug 2023; status: not yet recruiting.
02
Drugs
sacubitril + valsartan
03
Conditions
end-stage kidney disease (ESKD)heart failure (HF)
Beyond the preview
Go deeper on ChiCTR2300074610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300074610.